NCT06793709招募中不适用
Post-marketing Observational Study of Tasfygo Tablet 35 mg to Evaluate the Safety of Tasfygo in Patients With Unresectable Biliary Tract Cancer With FGFR2 Fusion Gene Positivity Who Progressed After Chemotherapy
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Number of Participants With Adverse Drug Reactions
研究概览
简要总结
The primary purpose of this study is to investigate the safety of Tasfygo.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1. Participants with unresectable biliary tract cancer with FGFR2 fusion gene positivity who are naïve to Tasfygo tablet and progressed after chemotherapy.
排除标准
- •Not applicable.
结局指标
主要结局
Number of Participants With Adverse Drug Reactions
时间窗: Up to 1 year
次要结局
- Percentage of Participants With Best Overall Response (BOR) Based on Physician's Assessment(Up to 1 year)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
A Study of Tazemetostat on Safety in Subject With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in JapaEUCTR2021-006398-41-Outside-EU/EEAEisai Co., Ltd.
已完成
不适用
Post-market clinical follow-up investigation of the marketed Extended Range of Vision IOL (Intraocular lens)h25H26Senile cataractOther cataractDRKS00005742Abbott Medical Optics Inc.147
招募中
4 期
APCEDEN® , Dendritic cell based Immunotherapy for the treatment of cancer.CTRI/2017/11/010583APAC Biotech Pvt Ltd
进行中（未招募）
不适用
Post-market clinical follow-up study to evaluate the performance and safety of Suprasorb® A + Ag wound dressing and rope in the treatment of chronic woundsPresence of a chronic wound according to the instruction for use:- venous leg ulcer or- arterial ulcer (ABPI > 0,5) or- arterial and venous leg ulcer (ABPI > 0,5) or- pressure ulcer (category II – IV) or- diabetic foot ulcer or- post-operative wound healing disturbance or- donor sites or mesh graphsL89.1L89.2L89.3Stage II decubitus ulcerStage III decubitus ulcerStage IV decubitus ulcerDRKS00014861ohmann & Rauscher GmbH & Co. KG9
进行中（未招募）
1 期
/AInflamatory Bowel Disease (IBD)MedDRA version: 20.1 Level: LLT Classification code 10021973 Term: Inflammatory bowel disease NOS System Organ Class: 100000004856EUCTR2014-005192-89-FIHospira UK Ltd.2,500